Xiangxue

In 1986, Luogang Pharmaceutical Factory was established and restructured into Guangzhou Xiangxue Pharmaceutical Co., Ltd. in 1997. It went public with an initial public offering (IPO) on the Shenzhen Stock Exchange in China in 2010 (Stock Code: 300147). Adhering to the business philosophy of "Beneficence, Perfection, and Innovation," the company has adopted the long-term development strategy of advancing traditional Chinese medicine (TCM) and modernizing TCM. After years of development, it has become a leading enterprise in TCM modernization and a national high-tech enterprise with independent intellectual property rights, proprietary brands, and self-innovation capabilities. It has formed a complete industrial chain encompassing TCM resource development, advanced TCM manufacturing, modern logistics and distribution, and new drug creation. Xiangxue Pharmaceutical has established eighteen companies in Guangdong, Beijing, Shanxi, Sichuan, Chongqing, Anhui, Yunnan, and Ningxia, investing in the construction of large-scale GMP production bases and GAP herbal planting bases. This has led to the formation of a comprehensive TCM health industry, including innovative TCM decoction pieces, proprietary Chinese medicines, functional health foods (beverages), and health preservation products, creating over ten thousand job positions in China.